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Abstract 
Background: Evidence suggests a link between the presence of subjective memory 
complaints (SMC) and lower volume of the hippocampus, 
one of the first regions to show neuropathological lesions in Alzheimer’s disease. 
However, it remains unknown whether this pattern of 
hippocampal atrophy is regionally specific and whether SMC are also paralleled by 
changes in peripheral levels of amyloid-beta (Aβ). 
Methods: The volume of hippocampal subregions and plasma Aβ levels were cross-
sectionally compared between elderly individuals with 
(SMC+; N = 47) and without SMC (SMC−; N = 48). Significant volume differences in 
hippocampal subregions were further correlated with 
plasma Aβ levels and with objective memory performance. 
Results: Individuals with SMC exhibited significantly higher Aβ1–42 concentrations 
and lower volumes of CA1, CA4, dentate gyrus, and 
molecular layer compared with SMC− participants. Regression analyses further 
showed significant associations between lower volume of the 
dentate gyrus and both poorer memory performance and higher plasma Aβ1–42 levels 
in SMC+ participants. 
Conclusions: The presence of SMC, lower volumes of specific hippocampal regions, 
and higher plasma Aβ1–42 levels could be conditions 
associated with aging vulnerability. If such associations are confirmed in longitudinal 
studies, the combination may be markers recommending 
clinical follow-up in nondemented older adults. 
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Subjective memory complaints (SMC) are common among elderly 
nondemented individuals, and they are generally perceived as a 
normal consequence of aging (1). However, numerous studies have 
found that SMC are associated with psychiatric symptoms (2), 
adverse health outcomes (3), and increased health care utilization 
(4). Evidence has also suggested that SMC may increase risk of progression 
to cognitive impairment and dementia (5). Consequently, 
individuals with SMC develop Alzheimer’s disease (AD) more frequently 
(6), have more functional deficits (7) and AD-type brain 
pathology than SMC− participants (8). 
As misperception may play an important role in self-reported 
memory problems, surrogate AD biomarkers should preferably 
accompany SMC-based assessments. Cerebrospinal fluid (CSF) and 
amyloid PET are the most reliable in vivo biomarkers of prodromal 
AD, but they are not suitable for screening purposes due to the invasive 
CSF sampling procedure and the high cost and limited availability 
of amyloid PET imaging (9). Alternatively, MRI-based AD biomarkers 
have demonstrated high sensitivity to prodromal AD (10). However, 
few studies to date have investigated the relationship between SMC 
and changes in hippocampal volume (11–14), and none of them has 
focused on specific regions within the hippocampal formation. 
Hippocampal subregions not only differ in gene expression, connectivity, 
and function (15,16) but are also affected by AD lesions 
with different chronologies (17). Indeed, postmortem studies have 
shown neurofibrillary degeneration in CA1 and subiculum as well as 
amyloid plaques in other hippocampal subregions during preclinical 
AD (18), suggesting that the hippocampus is unevenly affected during 
the continuum normal aging-AD. Because SMC appear early in this 
continuum, we hypothesize that CA1 could be one of the first hippocampal 
subregions affected. Moreover, altered neurogenesis in the 
hippocampus has been suggested as an early critical event in AD due 
to its relevance for neural plasticity and network maintenance (19). 
We would therefore expect lower volume of the dentate gyrus (DG) in 
SMC+ participants because, along with the olfactory bulb, the DG is 
the only site of neurogenesis in humans (20). If lower volume of CA1 
and DG results from some degree of synaptic and/or neuronal loss, it 
should also be accompanied by poorer memory performance. To evaluate 
these predictions, we have cross-sectionally compared the volume 
of different hippocampal subregions between elderly participants with 
and without SMC. We have further evaluated whether volume differences 
of hippocampal subregions are associated with alterations in 
memory performance in each group, separately. 
Accumulated evidence suggests that soluble amyloid-beta (Aβ) 
oligomers precede plaque formation and constitute the principal 
instigators of synapse loss and neuronal injury in AD (21), likely 
leading to synaptic deficits in asymptomatic elderly participants. 
Given that plasma enzyme-linked immunosorbent assays (ELISA) 
mainly detect soluble Aβ, another straightforward prediction of the 
present study is that SMC+ participants will show higher plasma Aβ 
concentrations than SMC− individuals, and that higher Aβ levels 
will be associated with lower volumes of hippocampal subregions 
affected during early stages of neurodegeneration. 
  
Methods 
Participants 
The study sample consisted of 95 nondemented elderly participants 
(mean age: 68.8 •} 3.8 years; range: 62–78 years) recruited from senior 
citizen’s associations, screening programs, and hospital outpatient 
services. Forty-seven of them reported SMC that were corroborated 
with the Memory Functioning Questionnaire and with a structured 
interview. The remaining 48 participants were clinically normal and 
did not report SMC as confirmed by the same instruments. 
All participants showed normal memory performance relative to 
appropriate reference values for age and education and underwent 
neurological examination, neuropsychological memory testing (Free 
and Cued Selective Reminding Test, Rey-Osterrieth Complex Figure 
Test, verbal paired associates subtest of the Wechsler Memory Scale, 
and the Camel and Cactus Test), and MRI evaluation (T1-3D and 
FLAIR). Individuals with medical conditions and/or history of disorders 
that may affect the cerebral integrity (eg, stroke, coronary heart 
diseases, diabetes, head trauma, neurodegenerative diseases, depression, 
hydrocephalus, intracranial mass, MRI infarcts, and use of psychoactive 
medication) were not allowed to participate in the study. All 
participants showed a global score of 0 (no dementia) in the Clinical 
Dementia Rating, as well as normal independent functions. Depression 
was excluded with the shorter version of the Geriatric Depression 
Scale (scores ≤ 5) given the association between plasma Aβ levels and 
depression in older adults (22). Participants gave informed consent 
prior to their inclusion in the study, which was approved by the Ethical 
Committee for Human Research at Pablo de Olavide University. 
Plasma Aβ Measurements 
Plasma Aβ levels were determined by a double-antibody sandwich 
ELISA (human Aβ1–40 and high sensitive Aβ1–42, Wako Chemicals, 
Tokyo, Japan). Briefly, venous blood samples were collected after 
overnight fasting in 10 mL K2-ethylenediaminetetraacetic acid 
(EDTA)-coated tubes (BD Diagnostics) and were immediately centrifuged 
(3,500 rpm) at 4°C for 5 minutes. Supernatant plasma was 
collected and aliquoted into 250 μL polypropylene tubes containing 
8.32 μL of a protease inhibitor cocktail (cOmplete Ultra Tablets 
mini, Roche). Plasma samples were stored at −80°C and thawed 
immediately before assay. 
Samples and standards were incubated overnight at 8°C with 
antibodies specific for Aβ1–40 and Aβ1–42 peptides, and the wells were 
read for absorption at 450 nm (Victor 3, PerkinElmer, Waltham, 
MA), according to the manufacturer’s instructions. Plasma Aβ levels 
were measured in duplicate (50 μL), and the average of the two 
measurements (pg/mL) was used for statistical analyses. Both interassay 
and intra-assay coefficients of variation were below 10%. The 
detection limit for these assays was 1.04 and 0.54 pg/mL for Aβ1–40 
and Aβ1–42, respectively. 
MRI Acquisition 
MRI studies were acquired on a whole-body Philips Achieva 3T scanner 
equipped with an 8-channel head coil. One high-resolution MP-RAGE 
(magnetization-prepared rapid gradient echo) T1-weighted anatomical 
sequence was obtained from each participant (0.8 mm3 isotropic 
voxel resolution, no gap between slices, TR = 11 ms, TE = 4.5 ms, flip 
angle = 8°, acquisition time = 9.1 minutes). 
Segmentation of Hippocampal Subregions 
MRI data were preprocessed using the analysis pipeline of Freesurfer 
v5.3 (http://surfer.nmr.mgh.harvard.edu/) involving intensity normalization, 
registration to Talairach space, skull stripping, segmentation 
of white matter, tesselation of the white matter boundary, and 
automatic correction of topological defects (23). Removal of nonbrain 
tissues was manually performed on a slice-by-slice basis for 
each participant to increase segmentation reliability. 
Hippocampal subregions were automatically segmented from 
the T1-weighted scans using a novel approach based on Bayesian 
inference and a probabilistic atlas of the hippocampal formation 
built upon ultra-high resolution (0.13 mm isotropic, on average), 
ex vivo MRI data from 15 cases (24). The following subregions 
resulted from hippocampal segmentation: parasubiculum, presubiculum, 
subiculum, CA1, CA3, CA4 subfields, granule cell layer 
of DG, hippocampus-amygdala-transition-area, fimbria, molecular 
layer (ML), hippocampal fissure, and tail. Segmentation results 
were visually inspected for errors in each participant. Figure 1 
shows the analysis pipeline to obtain volumes of hippocampal 
subregions. 
The intracranial volume of each individual was also estimated using 
the Freesurfer analysis pipeline. Skull-stripped images were revised and 
corrected manually to ensure that extracranial and skull structures 
were successfully removed while preserving intracranial structures.  
Statistical Analyses 
Statistical analyses were performed with SPSS v21 (SPSS Inc., 
Chicago, IL). Parametric statistics were used because the sample size 
was above 40 participants and the null hypothesis of non-normal 
distribution was rejected with the Kolmogorov–Smirnov test for 
demographic variables, memory scores, plasma Aβ measurements 
(ie, Aβ1–40, Aβ1–42), and hippocampal volumes. Group differences in 
demographics were assessed with unpaired t tests, with the exception 
of gender, which was evaluated with the chi-square test. Group differences 
in plasma Aβ levels (Aβ1–40, Aβ1–42, Aβ1–42/Aβ1–40 ratio) and 
 
Figure 1. Analysis pipeline to obtain volumes of hippocampal subregions. 
Left column: Automatic segmentation of hippocampal subregions relied on 
a computational atlas of the hippocampal formation derived from (i) ultrahigh 
resolution (0.13 mm isotropic resolution, on average) ex vivo MRI scans 
of 15 autopsy samples that were manually segmented into 13 different 
hippocampal subregions and (ii) a separate data set of in vivo, T1-weighted 
MRI scans of the whole brain (1 mm isotropic resolution) (24). Right column: 
The cerebral MRI of each participant was preprocessed and segmented 
using the analysis pipeline of Freesurfer; the output was used to initialize 
the hippocampal segmentation, from which the volume of hippocampal 
subregions was obtained. 
 
 
memory scores were assessed using a global multivariate analysis of 
covariance (MANCOVA) adjusted for age and gender. 
Mixed ANCOVAs, with the group (SMC− vs SMC+) as the 
between-participants factor, the hemisphere (left vs right) as the 
within-participants factor, and age and intracranial volume as covariates, 
were performed to inspect group differences in the volume of 
each hippocampal subregion. Gender was not included as a covariate 
in the general linear model because this variable did not reach 
statistical significance for any hippocampal subregion. 
Linear regression analyses were further conducted in each group 
separately to assess whether volume differences in any of the hippocampal 
subregions were related to alterations in memory performance 
obtained with different neuropsychological tests. A similar 
statistical approach was employed to test for significant associations 
between volume of hippocampal subregions and plasma Aβ levels. 
If correlations reached significance in at least one of the two groups, 
group differences between regression slopes were also computed. 
For the latter, the interaction between the group and either the MRI 
volume or the Aβ levels was introduced in the statistical model. All 
regression analyses were adjusted for age and intracranial volume. 
Permutation tests (N = 10,000 randomizations) were conducted to 
correct for multiple comparisons in all statistical analyses. 
Results 
Demographic Characteristics and Memory Functioning 
As shown in Table 1, elderly participants with and without SMC 
were homogeneous in demographic characteristics and performed 
similarly in objective memory tests. As expected, self-perception of 
memory was significantly affected in SMC+ (p = 10–8 for everyday 
memory; p = .001 for memory of texts; p = 10–5 for memory of past 
events) compared with SMC− participants. 
Plasma Aβ Levels 
Plasma Aβ concentrations significantly differed between the two 
groups (F3,89 = 6.67, p = .0004). The univariate ANCOVAs showed 
higher levels of Aβ1–42 (F1,91 = 7.56, p = .007) and higher Aβ1–42/Aβ1–40 
ratio (F1,91 = 15.76, p = .0001) in SMC+ compared with SMC− participants 
(see Table 1). 
Volume of Hippocampal Subregions 
Mean volumes of hippocampal subregions for each group are 
reported in Table 2. The mixed MANCOVA revealed lower hippocampal 
volumes in SMC+ participants with a consistent trend for 
greater atrophy of the left hemisphere (Table 2, corrected p values). 
More specifically, SMC+ individuals showed lower volumes of the 
whole hippocampus (p = .04), CA1 (p = .02), and CA4 (p = .03) 
subfields, DG (p = .02), and ML (p = .03) than SMC− participants. 
No significant differences were observed in the opposite direction for 
any hippocampal subregion (ie, lower volumes in SMC− compared 
with SMC+ participants). Figure 2B displays group differences in DG 
volumes. 
Relationship Between Volume of Hippocampal Subregions and Memory Functioning 
We next investigated whether volume differences of hippocampal 
subregions were associated with variations of memory performance 
in each group, separately. Regression analyses showed 
significant associations between regional hippocampal volume and performance of 
different memory tests in SMC+ participants. 
 
 
Table 1. Demographic, Aβ Measurements, and Memory Functioning 
 
 
Notes: Results are expressed as mean •} standard deviation. m/f = male/female; 
Aβ = amyloid-beta; FCSRT = Free and Cued Selective Reminding Test; 
MFQ = Memory Functioning Questionnaire; MMSE = Mini-Mental State Examination; 
ROCFT = Rey-Osterrieth Complex Figure Test; SMC = subjective 
memory complaints; WMS = Wechsler Memory Scale, third edition. 
*p < .01; **p < .001; ***p < .0001. 
 
 
 
 
 
 
 
 
Table 2. Volume of Hippocampal Subregions 
 
 
 
Notes: Results (in mm3) are expressed as mean •} standard deviation. 
DG = dentate gyrus; HATA = hippocampus-amygdala-transition-area; 
ML = molecular layer; SMC = subjective memory complaints. 
*p < .05. 
 
Thus, lower volumes of total hippocampus (β = 0.36, p = .009), 
DG (β = 0.33, p = .02), and ML (β = 0.31, p = .03) were related 
to poorer delayed memory in the Rey-Osterrieth Complex Figure 
Test. However, there was no interaction effect with group for any 
of these variables. Lower volumes of total hippocampus and ML 
were also associated with poorer semantic memory in the Camel 
and Cactus Test (β = 0.31, p = .02) and with poorer delayed 
memory in the Free and Cued Selective Reminding Test (β = 0.31, 
p = .03), respectively. Group differences in regression slopes only 
reached significance for the relationship between the volume of 
ML and delayed recall in the Free and Cued Selective Reminding 
Test (β = −0.9, p = .02), this relationship being stronger in SMC+ 
than in SMC− participants. Figure 2C shows significant associations 
between lower volume of DG and poorer delayed memory in 
SMC+ participants. 
Relationship Between Volume of Hippocampal Subregions and Plasma Aβ Levels 
Finally, we assessed whether lower volumes of hippocampal subregions 
were related to higher plasma Aβ1–42 levels. Regression analyses 
revealed that lower volumes of DG (β = −0.31, p = .03) and ML 
(β = −0.33, p = .01) were significantly associated with higher Aβ1–42 levels 
in SMC+ participants, but this relationship did not differ from the 
one shown by SMC− individuals. No other hippocampal subregions 
showed a significant relationship with plasma Aβ1–42 levels in any of 
the two groups. Figure 2D shows the significant relationship between 
lower volumes of DG and higher Aβ1–42 levels in SMC+ participants. 
 
 
 
Figure 2. Effects of SMC on structural integrity of DG. (A) A sample coronal 
slice of the hippocampus highlighting (in blue) the segmented DG. (B) Group 
differences in DG volume (mm3). (C) Significant association between lower 
volume of the DG and poorer memory performance in SMC+ participants. (D) 
Significant association between lower volume of the DG and higher plasma 
Aβ1–42 levels in the SMC+ group. Statistical analyses were all adjusted by age 
and ICV, and p values were previously corrected with permutation-based 
tests. Aβ = amyloid-beta; DG = dentate gyrus; ICV = intracranial volume; 
SMC = subjective memory complaints. 
 
 
Discussion 
The present study shows, for the first time, that nondemented elderly 
participants with self-reported memory complaints have lower volumes 
of specific hippocampal subregions (ie, CA1 and CA4 subfields, 
the granule cell layer of DG, and the ML) and higher concentrations 
of plasma Aβ1–42 than SMC− participants. These findings are in agreement 
with the high prevalence of pathological CSF values (25) and 
the high levels of AD-type neuropathological lesions (8) observed in 
SMC participants. Moreover, we have found that lower volumes of 
DG and the overlying ML in SMC+ participants not only are associated 
with poorer episodic and semantic memory, respectively, but 
also with higher plasma Aβ1–42 levels. 
Interestingly, the lower volumes of hippocampal subregions were 
restricted to the left side in SMC+ participants, corroborating earlier 
findings (12). In fact, there is evidence that gray matter reduction in 
the left hippocampus precedes clinical AD, this being a particularly 
useful biomarker of cognitive decline during asymptomatic stages 
(26). It might happen that the vulnerability of the left hippocampus 
to AD pathology can be extended to SMC+ individuals who are 
prone to develop faster cognitive decline or eventually AD. 
We found that SMC participants showed lower volume of the CA1 
subfield. Previous evidence suggests that neuronal loss in CA1 is not 
an age-related phenomenon but rather characterizes an overt AD process 
(27). Contrary to our initial hypothesis, lower volume of CA1 was 
not associated with lower memory performance in SMC+ participants. 
One possible explanation for this negative result is that early CA1 
dysfunctions are being compensated for by other mechanisms of neural 
plasticity elsewhere in the brain. Despite the lack of relationship, 
previous evidence has shown that CA1 atrophy predicts decline to 
mild cognitive impairment (MCI) in cognitively normal individuals 
(28) and subsequent conversion to AD (29), suggesting that lower 
CA1 volume associated with SMC may signal either incipient neurodegeneration 
or increased aging vulnerability. 
To our knowledge, this is the first study revealing lower volumes 
of CA4, DG, and overlying ML in SMC participants using in vivo 
MRI. One of our predictions was that SMC participants would have 
lower volume of the DG due to the prominent role of this structure 
in neurogenesis, and consequently in synaptic plasticity, which makes 
this hippocampal subregion extremely vulnerable to AD pathological 
mechanisms. Although the functional significance of neurogenesis in 
the adult human hippocampus remains to be determined, evidence 
suggests that hippocampal neurogenesis remains throughout old age 
(30,31). Altered neurogenesis in the hippocampus may affect discriminative 
learning and memory mainly due to the role of these regions 
in pattern separation, which require transformation of similar inputs 
into more discordant outputs (32). It is therefore not surprising that 
SMC+ participants showed a significant relationship between lower 
volume of DG and poorer episodic memory in the present study. 
Only one study to date has examined the relationship between 
objective memory and hippocampal volume in participants with SMC 
(12), although the influence of depressive symptoms could not be 
completely ruled out. We found that the lower the volume of DG, the 
poorer the memory performance in individuals with SMC. This result 
is consistent with previous evidence showing impaired memory performance 
together with structural and functional changes in CA3 and 
DG in MCI patients (33). Therefore, the relationship between DG volume 
and memory performance in individuals with either SMC or MCI 
provides strong support to the notion that neuroplasticity in the aging 
brain may be an important vulnerability factor for developing AD. 
Our study also showed that higher plasma Aβ1–42 levels were significantly 
associated with lower volume of the DG in SMC+ participants. 
Plasma concentrations of Aβ1–42 are elevated in familial AD 
with mutations in the presenilin (PS) or amyloid precursor protein 
(APP) genes (34), as well as in Down’s syndrome patients (35), and 
in first-degree relatives of AD patients at increased risk of developing 
AD (36). Furthermore, higher plasma Aβ1–42 levels have been associated 
with faster cognitive decline (37), higher atrophy of the temporal 
lobe in cognitively intact elderly participants (38), and conversion 
to MCI (39). Evidence suggests that cerebral and peripheral Aβ levels 
form a dynamic equilibrium that seems to be altered during AD 
progression (40). Thus, previous research has shown that elevated 
peripheral Aβ levels may enter the brain, accelerating AD pathogenesis 
(41), or reducing its clearance from the brain (42). Although 
studies considering plasma Aβ as a potential biomarker of dementia 
have yielded contradictory results (9), our findings suggest that combining 
plasma Aβ measurements with volume differences of specific 
regions of the hippocampal formation may be helpful in assessing 
aging vulnerability in elderly participants with SMC. 
We speculate that the association between DG atrophy and higher 
plasma Aβ1–42 concentration may signal incipient AD-related pathology 
in SMC+ participants. In line with this assumption, previous 
studies have shown that associations between CSF Aβ1–42 levels and 
patterns of cortical atrophy differ between asymptomatic elderly participants 
and MCI patients. Interestingly, significant correlations were 
restricted to the temporal lobe, medial parietal cortex, and posterior 
cingulate in MCI (43,44), whereas correlations with the temporal 
lobe were absent in asymptomatic elderly participants (45). All the 
above regions not only show high levels of amyloid PET retention 
in MCI and AD patients (46) but also are important common nodes 
of different hippocampal networks showing decreased functional 
connectivity in MCI (47). Future research should longitudinally 
assess whether the association between lower volume of DG and 
higher plasma Aβ1–42 levels in SMC+ participants is able to discriminate 
between older adults who experience faster decline from those 
who remain stable. If such association is confirmed, older adults with 
SMC may be a target population for applying novel pharmacological 
strategies aimed to modify AD pathological mechanisms. 
This study has some limitations that should be mentioned. First, 
participants lacked biomarkers of AD pathology (ie, CSF Aβ/tau and/ 
or amyloid PET) impeding the confirmation of preclinical AD in SMC+ 
participants. Second, the present study is cross-sectional, hindering the 
assessment of progression and therefore the validation of hippocampal 
volume changes and plasma Aβ1–42 results in this population. 
Furthermore, the hippocampal atlas was applied to 1 mm resolution 
T1 data, where the internal boundaries of hippocampal subregions are 
not clearly distinguishable. Although automated segmentations were 
visually inspected for errors in each individual to guarantee the reliability 
of the volume estimates, it should be noted that the internal 
boundaries of the hippocampal segmentation mostly rely on the prior 
knowledge encoded in the atlas rather than on the image contrast. 
Therefore, future research conducted with SMC+ participants should 
combine in vivo biomarkers of AD pathology with MRI hippocampal 
acquisitions of higher resolution in a longitudinal framework. This 
approach would hopefully contribute to reducing the required sample 
sizes for preventive clinical trials in AD and offer follow-up to elderly 
participants at higher risk in developing preclinical AD. 
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